Molecular Partners
Develops designed ankyrin repeat protein platform therapies used in ophthalmology, oncology, inflammation, and other therapeutic treatments.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
* | $20.0m | Post IPO Equity | |
| Total Funding | 000k | ||
| CHF | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 1932 % | (96 %) | (29 %) | - | - | 538 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (651 %) | 63 % | (773 %) | (1116 %) | - | (504 %) | 101 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (684 %) | 62 % | (881 %) | (1087 %) | - | (794 %) | (53 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 597 % | 27 % | 693 % | 978 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Molecular Partners is a biopharmaceutical company focused on developing innovative therapies for cancer patients. Operating in the biotechnology sector, the company specializes in creating a new class of custom-built medicines designed to overcome the limitations of existing cancer treatments. Their core product line includes DARPin® therapeutics, which are engineered proteins that offer high specificity and potency. Molecular Partners primarily serves healthcare providers, research institutions, and pharmaceutical companies. The business model revolves around research and development, clinical trials, and partnerships with larger pharmaceutical firms for commercialization. Revenue is generated through licensing agreements, milestone payments, and royalties from successful drug candidates. The company is committed to improving patient outcomes through collaborative and inclusive work practices, leveraging a diverse team of specialists to drive innovation.
Keywords: biopharmaceutical, cancer therapy, DARPin® therapeutics, biotechnology, clinical trials, healthcare providers, research institutions, pharmaceutical partnerships, licensing agreements, patient outcomes.